ASX - By Stock
|
RCE Biotech |
Re:
RCE Charts
|
|
baldymyer
|
2.1K |
625K |
2 |
17/04/21 |
17/04/21 |
ASX - By Stock
|
2.1K
|
625K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Encouraging Results Against SARS-CoV-2 Virus
|
|
baldymyer
|
81 |
21K |
11 |
10/11/20 |
10/11/20 |
ASX - By Stock
|
81
|
21K
|
11
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Appendix 4C and Activity Report
|
|
baldymyer
|
118 |
26K |
12 |
21/10/20 |
21/10/20 |
ASX - By Stock
|
118
|
26K
|
12
|
|
ASX - By Stock
|
RCE |
Re:
Ann: R327 Phase I Study - Australia's CMAX Clinical Facility
|
|
baldymyer
|
61 |
18K |
6 |
15/09/20 |
15/09/20 |
ASX - By Stock
|
61
|
18K
|
6
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Comment on Media Article Published in AFR
|
|
baldymyer
|
3 |
1.4K |
2 |
08/09/20 |
08/09/20 |
ASX - By Stock
|
3
|
1.4K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Comment on Media Article Published in AFR
|
|
baldymyer
|
3 |
1.4K |
4 |
08/09/20 |
08/09/20 |
ASX - By Stock
|
3
|
1.4K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive & Concentration-Dependent Efficacy Against COVID-19
|
|
baldymyer
|
96 |
25K |
4 |
08/09/20 |
08/09/20 |
ASX - By Stock
|
96
|
25K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Trading Halt
|
|
baldymyer
|
52 |
15K |
5 |
08/09/20 |
08/09/20 |
ASX - By Stock
|
52
|
15K
|
5
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Pause in Trading
|
|
baldymyer
|
52 |
16K |
5 |
07/09/20 |
07/09/20 |
ASX - By Stock
|
52
|
16K
|
5
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Pause in Trading
|
|
baldymyer
|
52 |
16K |
8 |
07/09/20 |
07/09/20 |
ASX - By Stock
|
52
|
16K
|
8
|
|
ASX - By Stock
|
EVE |
Re:
EVE chart to BREAKOUT to the UPSIDE
|
|
baldymyer
|
430 |
121K |
4 |
19/08/20 |
19/08/20 |
ASX - By Stock
|
430
|
121K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
Up another 10%
|
|
baldymyer
|
103 |
25K |
0 |
22/06/20 |
22/06/20 |
ASX - By Stock
|
103
|
25K
|
0
|
|
ASX - By Stock
|
EVE |
Re:
Product Launch
|
|
baldymyer
|
77 |
22K |
1 |
19/06/20 |
19/06/20 |
ASX - By Stock
|
77
|
22K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
Up another 10%
|
|
baldymyer
|
103 |
25K |
3 |
02/06/20 |
02/06/20 |
ASX - By Stock
|
103
|
25K
|
3
|
|
ASX - By Stock
|
EVE |
Re:
Ann: Company Update
|
|
baldymyer
|
76 |
20K |
9 |
28/05/20 |
28/05/20 |
ASX - By Stock
|
76
|
20K
|
9
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Response to ASX Price and Volume Query
|
|
baldymyer
|
46 |
11K |
3 |
28/05/20 |
28/05/20 |
ASX - By Stock
|
46
|
11K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Response to ASX Price and Volume Query
|
|
baldymyer
|
46 |
11K |
2 |
28/05/20 |
28/05/20 |
ASX - By Stock
|
46
|
11K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Response to ASX Price and Volume Query
|
|
baldymyer
|
46 |
11K |
2 |
27/05/20 |
27/05/20 |
ASX - By Stock
|
46
|
11K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
up over 10% on no news
|
|
baldymyer
|
87 |
21K |
3 |
27/05/20 |
27/05/20 |
ASX - By Stock
|
87
|
21K
|
3
|
|
ASX - By Stock
|
EVE |
Re:
Ann: Company Update
|
|
baldymyer
|
76 |
20K |
6 |
27/05/20 |
27/05/20 |
ASX - By Stock
|
76
|
20K
|
6
|
|
ASX - By Stock
|
EVE |
Re:
Ann: Company Update
|
|
baldymyer
|
76 |
20K |
9 |
27/05/20 |
27/05/20 |
ASX - By Stock
|
76
|
20K
|
9
|
|
ASX - By Stock
|
RCE |
Re:
up over 10% on no news
|
|
baldymyer
|
87 |
21K |
0 |
20/05/20 |
20/05/20 |
ASX - By Stock
|
87
|
21K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Data on RECCE 327 Against Influenza A
|
|
baldymyer
|
56 |
17K |
2 |
20/04/20 |
20/04/20 |
ASX - By Stock
|
56
|
17K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Trading Halt
|
|
baldymyer
|
59 |
18K |
2 |
19/04/20 |
19/04/20 |
ASX - By Stock
|
59
|
18K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Trading Halt
|
|
baldymyer
|
59 |
18K |
11 |
18/04/20 |
18/04/20 |
ASX - By Stock
|
59
|
18K
|
11
|
|
ASX - By Stock
|
RCE |
Re:
Ann: First-in-Human Clinical Trial Progress Update
|
|
baldymyer
|
79 |
22K |
0 |
14/04/20 |
14/04/20 |
ASX - By Stock
|
79
|
22K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
Ann: First-in-Human Clinical Trial Progress Update
|
|
baldymyer
|
79 |
22K |
4 |
06/04/20 |
06/04/20 |
ASX - By Stock
|
79
|
22K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
Ann: First-in-Human Clinical Trial Progress Update
|
|
baldymyer
|
79 |
22K |
3 |
06/04/20 |
06/04/20 |
ASX - By Stock
|
79
|
22K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Ann: First-in-Human Clinical Trial Progress Update
|
|
baldymyer
|
79 |
22K |
2 |
01/04/20 |
01/04/20 |
ASX - By Stock
|
79
|
22K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Ann: First-in-Human Clinical Trial Progress Update
|
|
baldymyer
|
79 |
22K |
2 |
31/03/20 |
31/03/20 |
ASX - By Stock
|
79
|
22K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Ann: First-in-Human Clinical Trial Progress Update
|
|
baldymyer
|
79 |
22K |
1 |
30/03/20 |
30/03/20 |
ASX - By Stock
|
79
|
22K
|
1
|
|
ASX - By Stock
|
EVE |
Re:
Ann: Appendix 4D and Half Year Report
|
|
baldymyer
|
29 |
536K |
6 |
25/02/20 |
25/02/20 |
ASX - By Stock
|
29
|
536K
|
6
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Efficacy Data in Kidney/UTI infections animal model
|
|
baldymyer
|
171 |
234K |
3 |
19/02/20 |
19/02/20 |
ASX - By Stock
|
171
|
234K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Efficacy Data in Kidney/UTI infections animal model
|
|
baldymyer
|
171 |
234K |
7 |
17/02/20 |
17/02/20 |
ASX - By Stock
|
171
|
234K
|
7
|
|
ASX - By Stock
|
EVE |
Re:
Ann: Investor Presentation
|
|
baldymyer
|
70 |
95K |
2 |
09/02/20 |
09/02/20 |
ASX - By Stock
|
70
|
95K
|
2
|
|
ASX - By Stock
|
EVE |
Re:
Tea Tree Plantation and fires??
|
|
baldymyer
|
7 |
3.9K |
4 |
24/01/20 |
24/01/20 |
ASX - By Stock
|
7
|
3.9K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
RCE has a potential solution to a problem bigger than cancer
|
|
baldymyer
|
52 |
26K |
2 |
23/01/20 |
23/01/20 |
ASX - By Stock
|
52
|
26K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
when is the phase 1 trial scheduled to start
|
|
baldymyer
|
91 |
35K |
1 |
03/01/20 |
03/01/20 |
ASX - By Stock
|
91
|
35K
|
1
|
|
ASX - By Stock
|
RCE Medicine |
Re:
Recce Pharmaceuticals (ASX:RCE)
|
|
baldymyer
|
43 |
26K |
4 |
31/12/19 |
31/12/19 |
ASX - By Stock
|
43
|
26K
|
4
|
|
ASX - By Stock
|
RCE Medicine |
Re:
Recce Pharmaceuticals (ASX:RCE)
|
|
baldymyer
|
43 |
26K |
4 |
31/12/19 |
31/12/19 |
ASX - By Stock
|
43
|
26K
|
4
|
|
ASX - By Stock
|
RCE Medicine |
Re:
Recce Pharmaceuticals (ASX:RCE)
|
|
baldymyer
|
43 |
26K |
5 |
31/12/19 |
31/12/19 |
ASX - By Stock
|
43
|
26K
|
5
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Corporate Presentation - December 2019
|
|
baldymyer
|
30 |
15K |
6 |
30/12/19 |
30/12/19 |
ASX - By Stock
|
30
|
15K
|
6
|
|
ASX - By Stock
|
RCE Medicine |
Re:
Recce Pharmaceuticals (ASX:RCE)
|
|
baldymyer
|
43 |
26K |
4 |
18/12/19 |
18/12/19 |
ASX - By Stock
|
43
|
26K
|
4
|
|
ASX - By Stock
|
RCE Medicine |
Re:
Recce Pharmaceuticals (ASX:RCE)
|
|
baldymyer
|
43 |
26K |
1 |
17/12/19 |
17/12/19 |
ASX - By Stock
|
43
|
26K
|
1
|
|
ASX - By Stock
|
RCE Medicine |
Re:
Recce Pharmaceuticals (ASX:RCE)
|
|
baldymyer
|
43 |
26K |
3 |
13/12/19 |
13/12/19 |
ASX - By Stock
|
43
|
26K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Corporate Presentation - December 2019
|
|
baldymyer
|
30 |
15K |
6 |
05/12/19 |
05/12/19 |
ASX - By Stock
|
30
|
15K
|
6
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Data for RECCE 327 in MRSA Burns Wound Infection
|
|
baldymyer
|
28 |
11K |
1 |
28/11/19 |
28/11/19 |
ASX - By Stock
|
28
|
11K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Data for RECCE 327 in MRSA Burns Wound Infection
|
|
baldymyer
|
28 |
11K |
6 |
27/11/19 |
27/11/19 |
ASX - By Stock
|
28
|
11K
|
6
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Trading Halt
|
|
baldymyer
|
31 |
14K |
5 |
25/11/19 |
25/11/19 |
ASX - By Stock
|
31
|
14K
|
5
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Opening Address at 2019 World Antibiotic Resistance Congress
|
|
baldymyer
|
57 |
17K |
3 |
14/11/19 |
14/11/19 |
ASX - By Stock
|
57
|
17K
|
3
|
|